# COPEN ACCESS

Check for updates

# Prognosis and persistence of smell and taste dysfunction in patients with covid 19: meta analysis with parametric cure modelling of recovery curves

Benjamin Kye Jyn Tan,<sup>1</sup> Ruobing Han,<sup>1</sup> Joseph J Zhao,<sup>1</sup> Nicole Kye Wen Tan,<sup>1</sup> Emrick Sen Hui Quah,<sup>1</sup> Claire Jing[Wen Tan,<sup>1</sup> Yiong Huak Chan,<sup>2</sup> Neville Wei Yang Teo,<sup>3,4</sup> Tze Choong Charn,<sup>3,4,5</sup> Anna See,<sup>3,4,5</sup> Shuhui Xu,<sup>3,4</sup> Nikita Chapurin,<sup>6</sup> Rakesh K Chandra,<sup>6</sup> Naweed Chowdhury,<sup>6</sup> Rafal Butowt,<sup>7</sup> Christopher S von Bartheld,<sup>8</sup> B Nirmal Kumar,<sup>9,10</sup> Claire Hopkins,<sup>11,12</sup> Song Tar Toh<sup>3,4</sup>

For numbered affiliations see end of the article

Correspondence to: S T Toh toh.song.tar@singhealth.com.sg (ORCID 0000ED003ED077E2457) Additional material is published online only. To view please visit the journal online.

Cite this as: *BMJ* 2022;378:e069503 http://dx.doi.org/10.1136/ bmj[2021[069503

Accepted: 14 June 2022

#### ABSTRACT OBJECTIVE

# To clarify in patients with covid 19 the recovery rate of smell and taste, proportion with persistent dysfunction of smell and taste, and prognostic factors associated with recovery of smell and taste.

Systematic review and meta analysis.

## DATA SOURCES

PubMed, Embase, Scopus, Cochrane Library, and medRxiv from inception to 3 October 2021.

## **REVIEW METHODS**

Two blinded reviewers selected observational studies of adults (≥18 years) with covid⊡9 related dysfunction of smell or taste. Descriptive prognosis studies with time⊡to⊡event curves and prognostic association studies of any prognostic factor were included.

## DATA EXTRACTION AND SYNTHESIS

Two reviewers extracted data, evaluated study bias using QUIPS, and appraised evidence quality using GRADE, following PRISMA and MOOSE reporting guidelines. Using iterative numerical algorithms,

# WHAT IS ALREADY KNOWN ON THIS TOPIC

Although smell and taste abnormalities have been extensively studied for diagnostic value in covid 19, little is known about their clinical course, with inconsistent evidence on the duration of recovery based on narrative reviews Whether covid 19 related chemosensory dysfunction is transient or permanent is unknown, and it is unclear what proportion of patients develop persistent dysfunction

The prognostic factors associated with smell and taste recovery (eg, initial severity of smell and taste dysfunction, concomitant symptoms) are not established

# WHAT THIS STUDY ADDS

Parametric cure models project that 5.6% and 4.4% of patients might develop long lasting self[Teported smell and taste dysfunction post[Lovid[19, respectively]] about 15 million and 12 million patients worldwide as of July 2022 Meta[Lanalyses of reconstructed time[Lo[Levent individual patient data (IPD) showed that at 30, 60, 90, and 180 days, respectively, about 74%, 86%, 90%, and 96% of patients self[Teported smell recovery and 79%, 88%, 90%, and 98% of patients self[Teported taste recovery, among patients who remained alive at the given time

Women were less likely to recover their sense of smell and taste, and patients with greater initial severity of dysfunction and those with nasal congestion were less likely to recover their sense of smell

timeItoIevent individual patient data (IPD) were reconstructed and pooled to retrieve distribution free summary survival curves, with recovery rates reported at 30 day intervals for participants who remained alive. To estimate the proportion with persistent smell and taste dysfunction, cure fractions from Weibull nonImixture cure models of plateaued survival curves were logit transformed and pooled in a two stage metaIanalysis. Conventional aggregate data metaIanalysis was performed to explore unadjusted associations of prognostic factors with recovery.

## MAIN OUTCOME MEASURES

The primary outcomes were the proportions of patients remaining with smell or taste dysfunction. Secondary outcomes were the odds ratios of prognostic variables associated with recovery of smell and taste.

## RESULTS

18 studies (3699 patients) from 4180 records were included in reconstructed IPD metaDanalyses. Risk of bias was low to moderate; conclusions remained unaltered after exclusion of four high risk studies. Evidence quality was moderate to high. Based on parametric cure modelling, persistent selfTreported smell and taste dysfunction could develop in an estimated 5.6% (95% confidence interval 2.7% to 11.0%,  $l^2=70\%$ ,  $\tau^2=0.756$ , 95% prediction interval 0.7% to 33.5%) and 4.4% (1.2% to 14.6%,  $l^2=67\%$ ,  $\tau^2$ =0.684, 95% prediction interval 0.0% to 49.0%) of patients, respectively. Sensitivity analyses suggest these could be underestimates. At 30, 60, 90, and 180 days, respectively, 74.1% (95% confidence interval 64.0% to 81.3%), 85.8% (77.6% to 90.9%), 90.0% (83.3% to 94.0%), and 95.7% (89.5% to 98.3%) of patients recovered their sense of smell  $(I^2=0.0$  7.2%,  $\tau^2=0.006$  0.050) and 78.8% (70.5%) to 84.7%), 87.7% (82.0% to 91.6%), 90.3% (83.5% to 94.3%), and 98.0% (92.2% to 95.5%) recovered their sense of taste (range of  $l^2=0.0172.1\%$ ,  $\tau^2=0.0001$ 0.015). Women were less likely to recover their sense of smell (odds ratio 0.52, 95% confidence interval 0.37 to 0.72, seven studies,  $l^2=20\%$ ,  $\tau^2=0.0224$ ) and taste (0.31, 0.13 to 0.72, seven studies, I<sup>2</sup>=78%,  $\tau^2$ =0.5121) than men, and patients with greater initial severity of dysfunction (0.48, 0.31 to 0.73, five studies,  $l^2=10\%$ ,  $\tau^2 < 0.001$ ) or nasal congestion (0.42, 0.18 to 0.97, three studies,  $l^2=0\%$ ,  $\tau^2(0.001)$  were less likely to recover their sense of smell.

#### CONCLUSIONS

A substantial proportion of patients with covid 19 might develop long lasting change in their sense of smell or taste. This could contribute to the growing burden of long covid.

SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42021283922.

#### Introduction

Change in the sense of smell and taste is highly prevalent in patients with covid 19, with 4050% of people on average reporting these symptoms globally,<sup>1</sup> <sup>2</sup> and up to 98% showing olfactory dysfunction when tested objectively.<sup>3</sup> These chemosensory impairments are often the sole warning symptoms and the strongest predictors of SARSICOVI2 infection.<sup>1 4</sup> Disturbances in these senses can include decreased (hyposmia or hypogeusia) or absent function (anosmia or ageusia),<sup>5 6</sup> distorted (parosmia or parageusia) or putrid sensations (cacosmia or cacogeusia),<sup>5 6</sup> or even hallucinations (phantosmia or phantogeusia).

Although change in sense of smell and taste has been extensively studied for diagnostic value, little is known about the clinical course of such symptoms post covid<sup>10</sup>9, with inconsistent evidence on the duration of recovery.<sup>7 8</sup> In particular, it is unknown whether covid<sup>11</sup>9 related chemosensory dysfunction is transient or permanent,<sup>8</sup> and it is uncertain what proportion of patients develop persistent dysfunction. Furthermore, the prognostic factors associated with smell and taste recovery are unclear. While some studies have reported associations with initial severity of dysfunction, age, and sex,<sup>910</sup> not all studies are in agreement,<sup>1112</sup> and the roles of viral load, concomitant symptoms, and medical history have not been well studied.

These factors raise important clinical questions relevant to patients and doctors, as persistent smell and taste dysfunction could be considered a focal neurological deficit<sup>13</sup> and can have an impact on quality of life and general health<sup>1415</sup> long after recovery from covid<sup>11</sup>9. Affected patients are often distressed as these impairments can hinder the enjoyment of food and create hygiene problems related to body odour and bad breath.<sup>16</sup> Smell and taste dysfunctions might also be associated with depressive symptoms,<sup>16</sup> malnutrition,<sup>17</sup> cognitive decline,<sup>18</sup> and mortality.<sup>19</sup> In the context of covid<sup>11</sup>9, smell dysfunction has been postulated as a possible marker of accelerated neurodegenerative disease,<sup>13</sup> and this symptom is an important feature of long covid.

Considering the potentially serious sequelae associated with smell and taste dysfunctions, and the need for doctors to counsel patients on their anticipated recovery course, it is essential to investigate the burden of persistent symptoms and identify relevant prognostic factors. We therefore performed a systematic review and meta Lanalysis to bridge this knowledge gap, using recent advances in graphical digitisation and computational inference to reconstruct time To Levent individual patient data (IPD) directly from published graphs. In our main analysis, we describe the cumulative incidence of smell and taste recovery in patients with covid 19 across time. With the aid of parametric statistical cure models, we estimate the proportion of patients with persistent covid 19 related dysfunction of smell and taste. Finally, using one stage and two stage meta analyses from reconstructed IPD and aggregate data, we identify the key prognostic factors associated with the duration and likelihood of recovery.

#### Methods

This review is reported in accordance with the Meta analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.<sup>20 21</sup> Supplementary table S1 includes the MOOSE checklist.

#### Search strategy

We searched five databases (PubMed, Embase, Scopus, and Cochrane Library for published studies, and medRxiv for preprints) from inception to 3 October 2021, using search terms for smell dysfunction, taste dysfunction, and covid 19 (see full search strategy in the supplementary methods). We also hand searched the bibliographies of included articles and relevant reviews but identified no additional relevant records.

# Study selection and eligibility criteria

At least two of four authors (RH, NKWT, ESHQ, BKJT) independently selected eligible studies (based on title and abstract, followed by full text articles), extracted relevant data, and evaluated the risk of bias in a blinded manner, with conflicts resolved by a senior author (STT). We included observational studies (including control arms from interventional studies) with adult participants (≥18 years) who were infected with SARSICoVID and experienced dysfunction of either smell or taste. We accepted selfTreported or objective psychophysical measurements of smell or taste dysfunction, and descriptive prognosis studies that described the time to recovery of smell or taste, if timeItoEvent (survival) analysis was used and KaplanD Meier or cumulative incidence curves provided. Studies that did not provide suitable curves, although potentially relevant,<sup>22 23</sup> were excluded as these did not permit the graphical reconstruction of IPD. For prognostic factor association studies, we included those that investigated any variable (eg, initial severity of smell or taste dysfunction, age, sex, body mass index (BMI), ethnicity) in association with the time taken or extent of recovery of smell or taste, versus patients with covid 19 with smell or taste dysfunction who did not have this variable. As we sought aggregate data, we accepted studies regardless of whether they provided survival curves. Descriptive prognosis studies that were initially excluded owing to lack of survival curves were relevaluated for prognostic factor associations and included whenever possible (fig 1). We excluded case reports, reviews, conference abstracts, animal studies, non English language publications, and studies that reported only combined smell and taste dysfunctions.




Fig 1 | PRISMA flow diagram of study selection process. Supplementary table S2 shows the 18 studies included in reconstructed individual patient data meta Danalyses, and supplementary tables S7 and S8. show the 72 studies included in conventional aggregate data systemic review (inclusive of 22 studies further used for conventional aggregate data meta Danalyses)

## Data extraction

We extracted key data (see supplementary methods) from each included article. To aid the reconstruction of IPD, we extracted step function values, timings, and number[at[Frisk tables from available vector and raster images of survivor or failure curves, which were processed and digitised using a semi[automated web based tool (WebPlotDigitizer, version 4.5). When necessary, we contacted authors for baseline number[] at[Fisk data.<sup>9</sup>

#### **Risk of bias**

To assess risk of bias at study level, we used the Quality In Prognosis Studies (QUIPS) tool, as recommended by the Cochrane Prognosis Methods Group.<sup>24</sup>


#### Statistical analyses

Initially, we reconstructed time to Event individual patient data (IPD) from digitised survivor or failure curves by solving the inverted Kaplan Meier product limit equations using iterative numerical algorithms.<sup>25</sup> We evaluated the accuracy of reconstruction using published methods (see supplementary methods).<sup>26</sup>

In the primary analysis, we used a non[parametric two stage random effects model to retrieve a distribution[free summary survival curve.<sup>27</sup> This method obtains a distribution[free summary survival curve by expanding the product limit estimator of survival for aggregated survival data. As the competing event of death was not accounted for, the recovery rates reported at 30 day intervals relate to the probability of recovery for patients who remain alive before the time. The extension of DerSimonian[Laird methodology for multiple outcomes was applied to account for between study heterogeneity.<sup>27</sup> We retrieved  $\tau^2$  values at each 15 day intervals using DerSimonian[Laird estimation. Weights were derived through inverse variance weighting.

We anticipated potential plateauing of the cumulative incidence curves, which might suggest a heterogeneous subpopulation of patients who do not recover their sense of smell or taste. Therefore, to estimate the proportion of patients with persistent smell or taste dysfunction, we fitted Weibull distributed nonImixture parametric cure models with a logistic link to explicitly model long term effects on each study[s survival curves, Median recovery time (95% Cl): 14.86 (12.68 to 20.29) days Recovery rate (95% Cl)

30 days: 0.74 (0.64 to 0.81),  $\tau^2$ =0.017,  $l^2$ =77.17% 60 days: 0.86 (0.78 to 0.91),  $\tau^2$ =0.017,  $l^2$ =53.07% 90 days: 0.90 (0.83 to 0.94),  $\tau^2$ =0.016,  $l^2$ =37.72% 120 days: 0.93 (0.86 to 0.96),  $\tau^2$ =0.014,  $l^2$ =24.58% 150 days: 0.95 (0.88 to 0.98),  $\tau^2$ =0.050,  $l^2$ =57.66% 180 days: 0.96 (0.90 to 0.98),  $\tau^2$ =0.006,  $l^2$ =0.00%



Median recovery time (95% Cl): 12.37 (10.29 to 16.35) days Recovery rate (95% Cl)

30 days: 0.79 (0.71 to 0.85),  $\tau^2$ =0.015,  $l^2$ =72.10% 60 days: 0.88 (0.82 to 0.92),  $\tau^2$ =0.000,  $l^2$ =0.00% 90 days: 0.90 (0.84 to 0.94),  $\tau^2$ =0.000,  $l^2$ =0.00% 120 days: 0.92 (0.86 to 0.96),  $\tau^2$ =0.000,  $l^2$ =0.00% 150 days: 0.97 (0.93 to 0.99),  $\tau^2$ =0.000,  $l^2$ =0.00% 180 days: 0.98 (0.92 to 1.00), NA




Fig 2 | Non[parametric random effects summary survival curve from reconstructed time] to Event individual patient data for recovery of sense of smell and taste after covid[19. 1 corresponds to 100%. Blue dashed line represents the summary survival curve; purple lines represent individual studies; filled in circles represent the last follow[]up time within the study; translucent blue band represents 95% confidence intervals (CIs) obtained by extension of Greenwood[]s formula with the delta method; solid pink and dashed pink lines represent the pooled proportion and the accompanying 95% CIs of patients with persistent dysfunction, derived from figure 3

> if plateaus were observed. The nonImixture cure model conservatively assumes that for all patients, the cure fraction may be eventually delineated, as the propensity for recovery reduces asymptotically to zero over time. Conversely, mixture cure models make the presumptive assumption that a proportion of patients, as reflected by the cure fraction, will never experience recovery, and this is independent of time. We used mixture cure models as a sensitivity analysis.

> To further optimise the precision of cure models, we included only Kaplan Meier curves with number

atTrisk tables, as followTup times of patients with censorship status were more accurately retrieved.25 The presence of survival curve plateaus were quantitatively determined using the area[under[the]] curve method, where the arealunderlthelcurve to median survival time >1 reflects a greater impact of long term survivors (or patients with persistent smell or taste dysfunction) on the survival curve pattern, and presence of a plateau.<sup>28</sup> Thereafter, logit transformed cure fractions and accompanying standard errors were pooled with generic inverse variance meta analyses. A random effects model was utilised, with the restricted maximum likelihood estimator to estimate  $\tau^2$  and the Hartung Knapp adjustment of test statistics and confidence intervals.<sup>29</sup> The pooled proportion, and corresponding 95% confidence intervals and 95% prediction intervals, of patients with persistent smell or taste dysfunction were then retrieved after back transformation.

To explore the prognostic factors associated with the time to recovery, we analysed aggregate data from other studies in a conventional two stage metalanalysis. Sufficient data were available to pool the unadjusted odds ratios of various patient characteristics in association with the likelihood of persistent smell or taste dysfunction. Whenever feasible for two stage metalanalyses, we assessed between study variability with  $\tau^2$  and measured the proportion of variability due to heterogeneity using the I<sup>2</sup> statistic.<sup>30</sup> We also assessed publication bias qualitatively through visual inspection of funnel plot asymmetry and quantitatively through Egger<sup>[s]</sup> bias.<sup>31</sup> When funnel plot asymmetry was observed, we used the trim[and[fill technique]] which assumes that small study effects are due to missing studies to impute potentially missing studies and relestimate the pooled effect.<sup>32</sup> We conducted all analyses in R (version 4.0.3) following guidance from the Cochrane handbook, and considered a two sided P value <0.05 as significant (see supplementary methods).

#### Certainty of evidence

We evaluated the quality of pooled evidence at the outcome level using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework,<sup>33</sup> modified for prognostic evidence.<sup>34</sup>

### Patient and public involvement

Patients and members of the public were not involved in the design and execution of the study, as this is a secondary analysis of published data. However, we plan to engage the public in the dissemination of our findings, such as, but not limited to, media coverage, social media engagement, newsletters, and public talks.

## Results

Figure 1 summarises the study selection process. From 4180 nonEduplicated records, selection based on initial title and abstract yielded 205 relevant articles. After full text review, we included 18 articles for

Source	Cure fraction (95% Cl)	Cure fraction (95% Cl)
Smell recovery		
Lee 2020		0.06 (0.03 to 0.13
Kumar 2021	•	0.04 (0.01 to 0.12
Andrews 2021		0.02 (0.00 to 0.50
Printza 2021		0.13 (0.06 to 0.24
Rashid 2021	•	0.02 (0.00 to 0.16
Prajapati 2021		0.03 (0.00 to 0.46
Sehanobish 2021		0.16 (0.09 to 0.26
Riestra-Ayora 2021	-•-	0.12 (0.08 to 0.19
Chapurin 2021	•	0.01 (0.01 to 0.04
Horton 2021	•	0.01 (0.00 to 0.10
Total	↓ ·	0.06 (0.03 to 0.11
Prediction interval		(0.01 to 0.34)
Heterogeneity: τ <sup>2</sup> =0.76 (0.13 to 2.87); P<0.01; I <sup>2</sup> =70%		
Taste recovery		
Lee 2020	<b>∲</b> •	0.08 (0.05 to 0.12
Andrews 2021		0.06 (0.02 to 0.1
Sehanobish 2021	<b>—</b>	0.09 (0.04 to 0.19
Chapurin 2021	•	0.01 (0.00 to 0.04
Horton 2021	•	0.01 (0.00 to 0.1
Total		0.04 (0.01 to 0.15
Prediction interval		(0.00 to 0.49)
Heterogeneity: τ <sup>2</sup> =0.68 (0.03 to 10.28); P=0.02; I <sup>2</sup> =67%		J
	0 0.2 0.4 0.6 0.8	1.0

Fig 3 | Random effects metalanalysis of Weibull nonlimixture cure fraction for individual studies of persistent smell and persistent taste dysfunction after covid 19.1 corresponds to 100%. Stretched purple diamonds are the pooled proportion with confidence intervals (CIs) for each random effects metalanalysis; symmetrical purple diamonds with horizontal lines are the study estimate with CIs, where diamond sizes reflect the relative weight apportioned to studies in the metalanalysis. The restricted maximum likelihood estimator was used to estimate  $\tau^2$ , and the Hartung Knapp adjustment was applied to test statistics and CIs

reconstructed IPD metalanalyses and 68 articles for aggregate data systematic review and metalanalyses.

#### Reconstructed IPD time loov ent meta analyses Study characteristics

Of 18 studies (3699 patients) included in reconstructed IPD meta analyses (see supplementary table S2),<sup>912 35148</sup> all were observational, with nine retrospective and nine prospective cohorts. Four studies were conducted in the community setting and 14 studies in the hospital setting. Among these 14 studies, four involved only healthcare workers, four involved inpatients, four involved outpatients, and two involved both inpatients and outpatients. Eight studies investigated smell recovery and 10 studies separately investigated smell and taste recovery. Seventeen studies measured smell using selfTreport and one study used both selfTreport and the objective Brief Smell Identification Test. All 10 studies that investigated taste recovery used self report. Most studies used a binary definition of recovery, although four studies of smell and three of taste provided further descriptive details on partial or complete recovery. The start point for assessment varied: 11 studies of smell and five of taste used the onset of dysfunction, two studies of smell and one of taste used a positive reverse transcriptase polymerase chain reaction (RTIPCR) SARSICOVID test result, and the remaining studies used clinical diagnosis of covidID9. Assessment of smell or taste was performed once in nine studies, twice in two studies, and at regular intervals of daily to monthly in the seven remaining studies until study conclusion.

Nine studies were conducted in Europe, four in North America, and five in Asia. The mean participant age ranged from 30.0 to 55.8 years. The percentage of male participants ranged from 29.0% to 79.4%. Using QUIPS, risk of bias was high in four studies, moderate in seven studies, and low in seven studies (see supplementary table S3). Our findings remained unaltered in sensitivity analyses excluding high risk studies (see supplementary figure S1).

# Reconstructed IPD meta Danalyses and cure models

Time[to[event data from 2201 and 1498 individual patients in 18 studies were available for further analysis. IPD reconstruction was of adequate quality and within acceptable error margins (see supplementary table S4 and supplementary figure S2). All except one study showed a plateau in the recovery curve within the follow[up time (see supplementary table S5).

# RESEARCH

Study	Log (odds ratio)	SE of log (odds ratio)	Odds ratio (95% Cl)	Odds ratio (95% Cl)
Age (per year increase)				
Ferdenzi 2021	-0.32	0.06	\$	0.72 (0.65 to 0.81)
Makaronidis 2021	-0.01	0.01	<b>\</b>	0.99 (0.97 to 1.01)
Shahrvini 2021	-0.01	0.02	•	0.99 (0.95 to 1.03)
Random effects model			-	0.90 (0.58 to 1.39)
Prediction interval				(0.07 to 11.18)
Heterogeneity: τ <sup>2</sup> =0.03 (0.	01 to 1.27); P<0.0	01; l <sup>2</sup> =93%		
Women				
Biadsee 2021	-0.63	0.84		0.53 (0.10 to 2.76)
Bliddal 2021	-0.98	0.34		0.38 (0.20 to 0.73)
Boscolo-Rizzo 2021	-0.51	0.34		0.60 (0.31 to 1.17)
Ferdenzi 2021	-0.61	0.17	<b>.</b>	0.54 (0.39 to 0.77)
Kim 2020	-0.17	0.27		0.85 (0.50 to 1.43)
Makaronidis 2021	-0.90	0.26		0.41 (0.24 to 0.68)
Shahrvini 2021	-1.56	0.62		0.21 (0.06 to 0.71)
Random effects model			•	0.52 (0.37 to 0.72)
Prediction interval			_	(0.31 to 0.87)
Heterogeneity: τ <sup>2</sup> =0.02 (0.	00 to 0.71); P=0.2	28; l <sup>2</sup> =20%		
Higher severity of dysfu	nction			
Boscolo-Rizzo 2021	-1.20	0.47		0.30 (0.12 to 0.76)
Kosugi 2020	-0.77	0.29		0.46 (0.26 to 0.82)
Makaronidis 2021	-0.53	0.27		0.59 (0.35 to 1.00)
Rojas-Lechuga 2021	-1.05	0.29		0.35 (0.20 to 0.62)
Song 2021	-0.20	0.41		0.82 (0.36 to 1.84)
Random effects model			4	0.48 (0.31 to 0.73)
Prediction interval			_	(0.29 to 0.78)
Heterogeneity: τ <sup>2</sup> =0.00 (0.	00 to 1.17); P=0.3	35; l <sup>2</sup> =10%		
Nasal congestion				
Boscolo-Rizzo 2021	-0.68	0.37		0.51 (0.24 to 1.06)
Jalessi 2021	-1.36	0.66		0.26 (0.07 to 0.95)
Shahrvini 2021	-1.05	0.74		0.35 (0.08 to 1.48)
Random effects model			-	0.42 (0.18 to 0.97)
Prediction interval				(0.03 to 4.99)
Heterogeneity: τ <sup>2</sup> =0.00 (0.	00 to 4.28); P=0.6	55; I <sup>2</sup> =0%		
Smoking				
Boscolo-Rizzo 2021	-0.57	0.33		0.56 (0.30 to 1.08)
Makaronidis 2021	-0.30	0.41		0.74 (0.33 to 1.66)
Shahrvini 2021	0.80	0.88		2.27 (0.40 to 12.86
Random effects model				0.69 (0.23 to 2.12)
Prediction interval				(0.03 to 18.81)
Heterogeneity: τ <sup>2</sup> =0.00 (0.				

Fig 4 | Conventional aggregate data two stage metalanalysis of various prognostic factors in association with the odds of smell recovery. Stretched purple diamonds are the pooled proportion with confidence intervals (CIs) for each random effects metalanalysis; symmetrical purple diamonds with horizontal lines are the study estimate with CIs, where diamond sizes reflect the relative weight apportioned to studies in the metalanalysis. Supplementary tables S7 and S8 show these studies, with complete references. The restricted maximum likelihood estimator was used to estimate  $\tau^2$ , and the Hartung Knapp adjustment was applied to test statistics and CIs

#### Recovery of smell

From the random effects distribution[Free summary survival curves, 74.1% (95% confidence interval 64.0% to 81.3%) of participants recovered their sense of smell at 30 days, 85.8% (77.6% to 90.9%) at 60 days, 90.0% (83.3% to 94.0%) at 90 days, and 95.7% (89.5% to 98.3%) at 180 days ( $I^2$ =0.0[77.2%,

 $\tau^2$ =0.006D.050), with a median recovery time of 14.9 days (95% confidence interval 12.7 to 20.3 days) (fig 2). Among four of the included studies that specified the degree of smell recovery,<sup>10 11 41 49</sup> between 12.8% and 30.4% of patients achieved partial recovery and 44.0% to 70.0% achieved full recovery at followLup.

Study	Log (odds ratio)	SE of log (odds ratio)	Odds ratio (95% Cl)	Odds ratio (95% Cl)
Women				_
Bliddal 2021	-0.98	0.34		0.38 (0.20 to 0.73)
Boscolo-Rizzo 2021	-0.51	0.34		0.60 (0.31 to 1.17)
Kim 2020	-0.14	0.31		0.87 (0.48 to 1.58)
Makaronidis 2021	-1.03	0.32		0.36 (0.19 to 0.68)
Meini 2020	-1.29	0.39		0.27 (0.13 to 0.58)
Miyazato 2021	-3.36	0.90	<b>→</b>	0.03 (0.01 to 0.20)
Nguyen 2021	-2.02	0.32		0.13 (0.07 to 0.25)
Random effects model			-	0.31 (0.13 to 0.72)
Prediction interval				(0.04 to 2.40)
Heterogeneity: τ <sup>2</sup> =0.51 (0	.14 to 5.06); P<0.0	01; l <sup>2</sup> =78%		
Higher severity of dysfu	nction			
Boscolo-Rizzo 2021	-1.20	0.47	;	0.30 (0.12 to 0.76)
Makaronidis 2021	0.14	0.30	-	1.15 (0.64 to 2.07)
Rojas-Lechuga 2021	0.39	0.31	•	1.47 (0.80 to 2.70)
Song 2021	-0.17	0.93		0.84 (0.14 to 5.21)
Random effects model			-	0.86 (0.27 to 2.71)
Prediction interval				(0.04 to 17.62)
Heterogeneity: τ <sup>2</sup> =0.36 (0	.00 to 6.58); P=0.3	35; l <sup>2</sup> =64%		
		0.0	1 0.1 1 10	100

Fig 5 | Conventional aggregate data two stage meta analysis of various prognostic factors in association with the odds of recovery. Stretched purple diamonds are the pooled proportion with confidence intervals (CIs) for each random effects meta analysis; symmetrical purple diamonds with horizontal lines are the study estimate with CIs, where diamond sizes reflect the relative weight apportioned to studies in the meta analysis. Supplementary tables S7 and S8 show these studies, with complete references. The restricted maximum likelihood estimator was used to estimate  $\tau^2$ , and the Hartung Knapp adjustment was applied to test statistics and CIs

Based on metalanalysis of logit transformed Weibull non mixture cure fractions, about 5.6% (95% confidence interval 2.7% to 11.0%,  $I^2=70\%$ ,  $\tau^2=0.756$ , prediction interval 0.7% to 33.5%) of patients might develop persistent dysfunction of smell (fig 3, see supplementary figure S3A). Funnel plot asymmetry was found (EggerIs test, P=0.031) (see supplementary figure S4A), and after trimEandEfill adjustment for asymmetry the pooled proportion increased to 11.6% (95% confidence interval 5.2% to 23.9%), suggesting that any publication bias would have caused an underestimation of the pooled proportion of patients with persistent dysfunction. Sensitivity analysis with mixture cure models yielded a similar pooled proportion of 6.6% (95% confidence interval 3.5% to 12.0%) (see supplementary figure S5A).

#### Recovery of taste

Recovery of taste (fig 2) occurred in 78.8% (95% confidence interval 70.5% to 84.7%) of patients at 30 days, 87.7% (82.0% to 91.6%) at 60 days, 90.3% (83.5% to 94.3%) at 90 days, and 98.0% (92.2% to 95.5%) at 180 days ( $I^2$ =16%,  $\tau^2$ =0.000D.015), with median recovery time of 12.4 days (95% confidence interval 10.3 to 16.3 days). Among three of the included studies that specified the degree of taste recovery, <sup>104149</sup> between 8.3% and 30.0% achieved partial recovery and 50.0% to 88.9% achieved full recovery.

Based on random effects metaLanalysis of logit transformed Weibull nonEmixture cure fractions,

about 4.4% (95% confidence interval 1.2% to 14.6%,  $I^2$ =0.0 $\Box$ /2.1%,  $\tau^2$ =0.684, 95% prediction interval 0.2% to 49.0%) of patients might develop persistent taste dysfunction (fig 3, see supplementary figure S3B). Visual inspection of the funnel plot showed no evidence of asymmetry to suggest small study effects (see supplementary figure S4B). Sensitivity analysis with mixture cure models yielded a slightly higher pooled proportion of 8.2% (95% confidence interval 4.1% to 15.7%) (see supplementary figure S5B).

### Aggregate data systematic review and meta analyses

Since the reconstructed IPD metalanalyses provided only a limited set of prognostic factors, we conducted a systematic review to investigate all prognostic factors associated with the likelihood, duration, and extent of smell and taste recovery in patients postfrovid[19. A total of 80 prognostic factors for smell and taste recovery were reported in 68 studies, comprising 11 personal characteristics, 20 symptoms, 4 characteristics of smell or taste dysfunction, 7 characteristics of covid[19 disease, 11 past medical conditions, 16 medical interventions or treatments, and 11 biochemical variables. These findings are summarised first by individual studies (see supplementary table S6) and then by prognostic factors (see supplementary table S7).

BMI, most symptoms (cough, fatigue, rhinorrhoea, sore throat, muscle and joint pains), and medical

comorbidities (cardiovascular disease, diabetes, sinonasal disease) appear to have little correlation with the recovery of smell and taste in covid[19. Dyspnoea and treatment with steroids were associated with smell recovery in several studies. It remains equivocal if biochemical variables can predict recovery, with few isolated studies showing the importance of immunoglobulin levels, neutrophil counts, and platelet counts. The virus variant of SARSICOVI2 was not reported in association with smell or taste recovery.

## Aggregate data meta Danalyses of prognostic factors

Sufficient data were available to perform a conventional two stage meta analysis of reported unadjusted odds ratios of various factors in association with the likelihood of smell and taste recovery. Fourteen studies reporting 37 estimates were included in meta lanalyses (fig 4 and fig 5). Female sex was strongly associated with lower likelihood of recovery of smell (odds ratio 0.52, 95% confidence interval 0.37 to 0.72, seven studies,  $I^2=20\%$ ,  $\tau^2=0.0224$ ) and taste (0.31, 0.13) to 0.72, seven studies,  $I^2 = 78\%$ ,  $\tau^2 = 0.5121$ ). Greater severity of smell dysfunction was associated with lower likelihood of smell recovery (0.48, 0.31 to 0.73, five studies,  $I^2=10\%$ ,  $\tau^2<0.0001$ ) but not of taste recovery. Nasal congestion was associated with lower likelihood of smell recovery (0.42, 0.18 to 0.97, three studies,  $I^2=0\%$ ,  $\tau^2<0.001$ ). Age (per year increase) and smoking were not associated with smell recovery.

## Quality of evidence

Using the GRADE framework (see supplementary tables S8 and S9), we judged the certainty of evidence for each outcome as high, moderate, or low quality. We found high quality evidence for the descriptive prognosis of smell and taste recovery based on our reconstructed IPD metalanalysis. The evidence for the rate of persistent dysfunction (cure fraction) and for prognostic associations were of moderate to high quality.

#### Discussion

Smell and taste disorders tended to be overlooked by clinicians before the covid 19 pandemic, possibly because these senses were considered as unessential for life compared with vision and hearing.<sup>50</sup> As a result of the covid 9 pandemic, patients and doctors may now be aware that these are major problems that could adversely impact quality of life, personal bocial functioning, mental health, general health, and safety, long after patients recover from covid 9.

In this metalanalysis of timeltolevent data from 3699 patients in 18 studies, an estimated 74%, 86%, 90%, and 96% of patients selfTreported smell recovery and 79%, 88%, 90%, and 98% selfTreported taste recovery at 30, 60, 90, and 180 days, respectively. On the basis of parametric cure models, persistent smell or taste dysfunction might develop in about 5% of patients. Sensitivity analyses suggest this could be an underestimate. Female sex was associated with poorer recovery of both smell and taste, whereas greater

initial severity of dysfunction and nasal congestion were associated with poorer smell recovery only.

#### Comparison with other studies

This study used comprehensive, flexible statistical modelling to estimate the recovery curves and the proportion of patients who develop persistent smell and taste dysfunction postCrovidCl9. We used statistical cure models to investigate recovery from smell and taste dysfunction postCrovidCl9, and potentially our methods could be expanded to cover other major symptoms.

Our recovery curves are consistent with the findings of recent studies, which suggest that recovery from smell and taste dysfunction mostly occurs early in the course of covid<sup>11</sup>9.<sup>7 51</sup> More importantly, our cure models are consistent with other studies that explored the point prevalence of persistent dysfunction at long follow Lup durations of six months to one year. 22 23 49 52 We had excluded these studies as they did not provide appropriate graphs for reconstruction of IPD for this metalanalysis. These studies reported 9.0% of patients having little or no improvement in sense of smell at six months52; and 7.0 B.6% still had functional anosmia or persistent to worsening smell or taste impairment at one year,<sup>22 49</sup> which corresponds with our cure model predictions of 3111% of patients who develop persistent dysfunction. This provides support for the external validity of our findings and suggests that these patients are less likely to experience recovery. Nonetheless, recovery even after many years remains possible, based on previous studies of postIviral olfactory loss<sup>53</sup>; thus patients with covid<sup>1</sup>9 should be followed to over the long term.

The differential recovery rates could be explained by the underlying mechanisms of smell and taste dysfunction postcovid 19. Briefly, conductive barriers can prevent odorants and tastants from reaching receptors, and sensorineural interference can block sensory receptor function or signal transmission to the brain. Sensorineural mechanisms are currently thought to be the predominant mechanism of covid 19 related smell dysfunction,54 55 although conductive mechanisms have been implicated too.56 SARSICoVID infects and eliminates most olfactory epithelial support (sustentacular) cells that express angiotensin converting enzyme<sup>D</sup>, which leads to olfactory neuron deciliation and necrosis.55 57 Varying regeneration speed of support cells and sensory neurons, influenced by the degree of inflammation, could explain the delayed smell recovery. Stem cell damage and severe inflammation may also prolong smell dysfunction by slowing the regeneration of olfactory epithelial.<sup>57</sup> For taste dysfunction, binding of SARSICoVID to angiotensin converting enzyme<sup>D</sup> receptors in the salivary glands could impair salivary flow, leading to ConductiveD taste dysfunction.<sup>58</sup> Viral binding with oral mucosal cells might trigger inflammation, abnormal cell turnover, and reduced tastebud sensitivity and thus sensorineural taste dysfunction,58 59 which may have varying regeneration speed. As these hypotheses have

not been explored in association with recovery rates, further mechanistic research is warranted among the different patient subpopulations with rapid recovery or persistent dysfunction.

Although it is unsurprising that higher initial severity of smell dysfunction may prolong recovery, it is not clear why female sex is associated with poorer recovery and is notably consistent with previous reports of postEviral smell dysfunction disproportionately affecting women.<sup>60</sup> One reason could be the better baseline olfaction and gustation in female participants,61 62 which may result in greater sensitivity to changes and a larger subjective impairment. Biological explanations are also possible, as oestrogen upregulates the expression of angiotensin converting enzyme<sup>D</sup>, and the enzyme<sup>I</sup>s gene is located on the X chromosome.63 These findings suggest that the angiotensin converting enzyme<sup>D</sup> receptor<sup>D</sup> the binding site of SARS<sup>C</sup>OV<sup>D</sup> virus, may have higher expression in women, or may express heterodimers that alter virus binding,<sup>64</sup> thus potentially enhancing viral invasion in women. Furthermore, immune related X linked genes are more activated in the immune cells of women.<sup>64</sup> Although acute inflammation promotes olfactory epithelial regeneration, chronic inflammation is detrimental to recovery.65 66 These factors could possibly account for the poorer observed recovery in women and should be investigated further. It is also unclear why recovery of taste occurs faster in Asian countries. One possibility is the ethnic differences between continents, which may affect smell or taste perception,  $^{67}$  as well as susceptibility to SARSICOVI2 virus.  $^{68}$  Alternatively, intercontinental genetic variations in SARSICoVID might influence biological mechanisms.<sup>1 68</sup> As many of the included studies did not specify the ethnic distribution of participants, however, further research is required to explain this phenomenon.

Our findings suggest an important burden from persistent smell and taste dysfunctions. Presently it is unknown if these sensory impairments might be associated with long term health related consequences. Smell dysfunction could predict the development of depression<sup>69</sup> and is potentially associated with neurodegenerative disorders, often heralding neurological and cognitive manifestations by several years.<sup>70</sup> Although recent studies of long covid have already reported a substantial burden of brain fog,<sup>71</sup> anxiety, and depression,<sup>72</sup> it remains uncertain if persistent smell dysfunction after covid[19 might prognosticate an increased risk of long term neurological sequelae or neurodegenerative disorders.<sup>13</sup> With more than 550 million people worldwide confirmed as having covid 19 as of July 2022, of whom about 50% report smell or taste dysfunction,<sup>2</sup> just 5.6% and 4.4% of patients with persistent smell and taste dysfunction translates to more than 15 million and 12 million patients with long term smell and taste dysfunctions, respectively. These patients may require further investigation, longitudinal follow Lup, and appropriate treatment.

the**bmj** | *BMJ* 2022;378:e069503 | doi: 10.1136/bmj-2021-069503

Finally, these findings should also be considered in the light of recent viral mutations. The omicron SARS CoVD2 variant is associated with a less noticeable reduction in loss of smell and taste compared with the delta and alpha variants.<sup>73</sup> This has contributed to increasing difficulty in detecting omicron using a symptom based testing approach. In particular, one large study found that only 1316% of patients lost their sense of smell and taste during the period when the omicron variant was dominant, compared with 44% when the delta variant dominated.<sup>73</sup> This may be secondary to alterations in the omicron spike protein,<sup>74</sup> which might result in less effective cell membrane fusion and olfactory host cell entry. Therefore, smell and taste recovery could also follow a different course after an omicron related infection. Although smell and taste dysfunction are less common with omicron, the fourfold transmissibility of omicron compared with the delta variant may still imply a net increase in the prevalence of chemosensory disorders.<sup>75</sup> As we found no relevant studies in our systematic search that stratified recovery according to SARSICoVID variant, this remains an important area of future research.

## Strengths and limitations of this study

The strengths of this study lie in the rigorous prespecified protocol of systematic searching, bias assessment, and quality grading, following international guidelines. Only four studies had a high risk of bias; the conclusions remained unaltered after their exclusion. The use of reconstructed IPD allowed flexible and comprehensive statistical modelling of recovery curves, with little heterogeneity detected. Nonetheless, several limitations should be acknowledged. Firstly, all included studies in the reconstructed IPD meta analyses relied on self reported recovery of smell and taste. These senses are closely associated, and often reported as overlapping symptoms<sup>1 76</sup>; possibly because members of the public often use DtasteD to describe flavour in food. In biology, flavour is actually a function of retronasal olfaction, whereas taste, or gustation, is the ability to differentiate between sweet, sour, salty, bitter, and umami.<sup>77</sup> Consequently, the prevalence of objectively assessed gustatory deficits may be lower than when selfTreported.<sup>77 78</sup> Patient reported recovery may thus be difficult to interpret, as many cases of taste dysfunction might actually be due to impaired olfaction rather than gustation.77 Similar limitations in subjective bijective concordance may exist, albeit to a smaller extent, when evaluating olfaction.<sup>52</sup> In our review, the only included study that compared objective assessments of smell with subjective assessments found that selfTreported recovery (defined as 10/10 on a visual analogue scale of smell function) underestimated recovery compared with objective assessments.<sup>44</sup> This difference, however, disappeared when selfTreported recovery was defined as 8/10 on the same scale.<sup>44</sup> Other studies found the opposite that self report overestimates recovery.23 This might be relate to the different objective tests used, or imply true clinical variations in prevalence, or that patients are selfTreporting cacosmia, phantosmia, and

parosmia, found in up to 43.1% of patients during recovery.<sup>52</sup> Regardless, as the primary aim of this work is to guide doctors in counselling patients with smell and taste dysfunction postEcovid[19, we view self] reported outcomes as most reflective of the patients perspective, and thus most relevant for patient counselling. Secondly, we did not find sufficient data to quantitatively analyse the completeness of recovery nor specific smell and taste dysfunction subtypes (eg, parosmia, cacosmia). These warrant further investigation, as a constant putrid odour is arguably more distressing than the inability to smell. Thirdly, half the included studies were retrospective and potentially subjected to recall bias. Therefore, our findings should be treated with caution and may be updated once further long term prospective data become available. Fourthly, as the pandemic has evolved over time, particularly with respect to vaccines, treatments, lockdowns, masks, and variants, the inherent clinical and methodological heterogeneity of the included studies might limit generalisation. Fifthly, as nearly all the included studies did not account for the competing event of death, the proportions reported in the IPD metaLanalyses relate to the probability of recovery for participants who remained alive before the given time. Sixthly, the available aggregate data largely used odds ratios to measure the association; these do not account for the time varying effects shown by our reconstructed IPD metaCanalyses. Further work should focus also on summarising adjusted prognostic associations, to assess added prognostic value over and above existing prognostic factors. Finally, the time based results shown in our reconstructed IPD metalanalyses are descriptive of the whole population and not necessarily of any individual patients recovery course.

#### Conclusions

In this metalanalysis with parametric cure modelling of timeItoLevent data from 3699 patients in 18 studies, we identified a major burden of long term self reported smell and taste abnormalities, with about 5% of patients developing persistent dysfunction. This outcome might contribute to the growing burden of long covid. Women were less likely to recover their sense of smell and taste. Patients with higher initial severity of dysfunction and patients with nasal congestion were also less likely to recover their sense of smell. While most patients are expected to recover their sense of smell or taste within the first three months, a major subpopulation of patients might develop long lasting dysfunction. These patients require timely identification, personalised treatment, and long term follow Lup for associated sequelae. Our findings are likely to be of substantial relevance to general doctors and otolaryngologists in the counselling of patients with smell and taste disorders post covid 19.

#### **AUTHOR AFFILIATIONS**

<sup>1</sup>Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>2</sup>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore <sup>3</sup>Surgery Academic Clinical Program, SingHealth, Singapore <sup>4</sup>Department of Otorhinolaryngology[Head and Neck Surgery, Singapore General Hospital, Singapore

<sup>5</sup>Department of Otorhinolaryngology[Head and Neck Surgery, Sengkang General Hospital, Singapore

<sup>6</sup>Department of OtorhinolaryngologyEHead and Neck Surgery, Vanderbilt University Medical Centre, Nashville, TN, USA
<sup>7</sup>Department of Molecular Cell Genetics, L Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
<sup>8</sup>Department of Physiology and Cell Biology, School of Medicine, University of Nevada, Reno, NV, USA

<sup>9</sup>Wigan and Leigh Teaching NHS Foundation Trust, Wrightington, UK <sup>10</sup>Edge Hill University Medical School, Orsmkirk, UK

<sup>11</sup>Department of Otorhinolaryngology[Head and Neck Surgery, Guyís and St Thomasí Hospitals, London, UK

<sup>12</sup>Kingís College, London, UK

We thank the patients and investigators of the included primary studies for enabling this pooled analysis, Yi Xuen Chai for reviewing our manuscript, and Jun Heng Lor for his mathematical insights. CH is a colcorresponding author (claire.hopkins@gstt.nhs.uk).

Contributors: BKJT, RH, and JJZ contributed equally to this work. BKJT conceived the study. BKJT, RH, NKWT, ESHQ, JJZ, YHC, NWYT, and STT designed the study. RH, NKWT, ESHQ, CJWT, and BKJT collected the data. BKJT, JJZ, YHC, NKWT, and NC analysed the data; all authors contributed to data interpretation. BKJT, RH, JJZ, NKWT, ESHQ, and CJWT wrote the manuscript; all authors contributed to critical revision for important intellectual content. STT contributed to overall supervision; all authors provided approval for publication. BKJT, RH, and JJZ are the guarantors. All authors have made important intellectual contributions and have seen and approved the manuscript for submission. The corresponding authors attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: This study received no specific funding. BKJT is supported by the Singapore Government Public Service Commission Scholarship and SingHealth Medical Student Talent Development Award. CSvB is supported by grant GM103554 from the National Institutes of Health

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not required.

Data sharing: Additional data may be obtained from corresponding author STT (toh.song.tar@singhealth.com.sg) on reasonable request. The manuscriptis guarantors (BKJT, RH, JJZ) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

Dissemination to participants and related patient and public communities: The results of the study will be published in a press release and on social media channels.

Provenance and peer review: Not commissioned; externally peer reviewed.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BYINC 4.0) license, which permits others to distribute, remix, adapt, build upon this work nonEcommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is nonE commercial. See: http://creativecommons.org/licenses/byEhc/4.0/.

- 1 Lechien JR, ChiesaIEstomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mildItoImoderate forms of the coronavirus disease (COVIDII 9): a multicenter European study. *Eur Arch Otorhinolaryngol* 2020;277:2251IB1. doi:10.1007/ s00405ID20ID5965II
- 2 von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in COVIDE1 9 Patients: A Systematic Review and MetaEanalysis Reveals Significant Ethnic Differences. ACS Chem Neurosci 2020:11:2944E61. doi:10.1021/acschemneuro.0c00460
- 3 Moein ST, Hashemian SM, Mansourafshar B, KhorramlTousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVIDEI 9. Int Forum Alleray Rhinol 2020;10:944[50. doi:10.1002/alr.22587

# RESEARCH

- 4 Rocke J, Hopkins C, Philpott C, Kumar N. Is loss of sense of smell a diagnostic marker in COVID⊡19: A systematic review and meta⊡ analysis. Clin Otolaryngol 2020;45:914⊡2. doi:10.1111/coa.13620
- 5 İşlek A, Balcı MK. Phantosmia with COVIDII 9 Related Olfactory Dysfunction: Report of Nine Case. Indian J Otolaryngol Head Neck Surr 2021:1/B. Published online 12 March
- 6 Ercoli T, Masala C, Pinna I, et al. Qualitative smell/taste disorders as sequelae of acute COVIDE 9. Neurol Sci 2021;42:4921E. doi:10.1007/510072ED21ED5611E6
- Santos REA, da Silva MG, do Monte Silva MCB, et al. Onset and duration of symptoms of loss of smell/taste in patients with COVIDEL9: A systematic review. *Am J Otolaryngol* 2021;42:102889. doi:10.1016/j.amjoto.2020.102889
- 8 Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori[Asenso R. Smell and Taste Dysfunction in Patients With COVIDIL 9: A Systematic Review and Meta[analysis. Mayo Clin Proc 2020;95:1621[B1. doi:10.1016/j.mayocp.2020.05.030
- 9 Chapurin N, Totten DJ, Chaballout B, et al. Differential olfactory outcomes in COVIDE 9: A large healthcare system population study. Int Forum Allergy Rhinol 2022;12:108E 1. doi:10.1002/alr.22870
- 10 Paderno A, Mattavelli D, Rampinelli V, et al. Olfactory and Gustatory Outcomes in COVIDID: A Prospective Evaluation in Nonhospitalized Subjects. Otolaryngol Head Neck Surg 2020;163:1144(D). doi:10.1177/0194599820939538
- 11 Jalessi M, Bagheri SH, Azad Z, et al. The outcome of olfactory impairment in patients with otherwise paucisymptomatic coronavirus disease 2019 during the pandemic. *J Laryngol Otol* 2021;135:426 35. doi:10.1017/S0022215121001110
- 12 Sehanobish E, Barbi M, Fong V, et al. COVIDII 9IInduced Anosmia and Ageusia Are Associated With Younger Age and Lower Blood Eosinophil Counts. Am / Rhinol Allergy 2021;35:830IP. doi:10.1177/19458924211004800
- 13 Xydakis MS, Albers MW, Holbrook EH, et al. PostIviral effects of COVIDII 9 in the olfactory system and their implications. *Lancet Neurol* 2021;20:753I61. doi:10.1016/S1474I4422(21)00182I4
- 14 Tan BKJ, Man REK, Gan ATL, et al. Is Sensory Loss an Understudied Risk Factor for Frailty? A Systematic Review and Meta[analysis. J Gerontol A Biol Sci Med Sci 2020;75:2461[70.
- 15 Choi JS, Jang SS, Kim J, Hur K, Ference E, Wrobel B. Association Between Olfactory Dysfunction and Mortality in US Adults. *JAMA Otolaryngol Head Neck Surg* 2021;147:49E55. doi:10.1001/ jamaoto.2020.3502
- 16 Croy I, Nordin S, Hummel T. Olfactory disorders and quality of lifeIIan updated review. Chem Senses 2014;39:185ID4. doi:10.1093/ chemse/bjt072
- 17 Fluitman KS, Hesp AC, Kaihatu RF, et al. Poor Taste and Smell Are Associated with Poor Appetite, Macronutrient Intake, and Dietary Quality but Not with Undernutrition in Older Adults. J Nutr 2021;151:605II 4. doi:10.1093/jin/nxa400
- 18 Dintica CS, Marseglia A, Rizzuto D, et al. Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. *Neurology* 2019;92:e700[9. doi:10.1212/ WNL.00000000006919
- 19 Pang NYLL, Song HJJMD, Tan BKJ, et al. Association of Olfactory Impairment With AllCause Mortality: A Systematic Review and Metall analysis. JAMA Otolaryngol Head Neck Surg 2022;148:436[45.
- Stroup DF, Berlin JA, Morton SC, et al. MetaBanalysis of observational studies in epidemiology: a proposal for reporting. MetaBanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008E12. doi:10.1001/jama.283.15.2008
- 21 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:10.1136/bmj.n71
- 22 BoscoloRizzo P, Guida F, Polesel J, et al. SelfTreported smell and taste recovery in coronavirus disease 2019 patients: a oneQear prospective study. Eur Arch Otorhinolaryngol 2022;279:515[20. doi:10.1007/s00405[D211b6839]W
- 23 BoscoloIRizzo P, Menegaldo A, Fabbris C, et al. SixIMonth Psychophysical Evaluation of Olfactory Dysfunction in Patients with COVIDIL 9. Chem Senses 2021;46:bjab006. doi:10.1093/chemse/bjab006
- 24 Hayden JA, van der Windt DA, Cartwright JL, CDtD P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158:280IG. doi:10.7326/0003I4819D158I4D 201302190ID0009
- 25 Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan[Meier survival curves. *BMC Med Res Methodol* 2012;12:9. doi:10.1186/1471[D288[I]2[D
- 26 Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published KaplandMeier survival curves. BMC Med Res Methodol 2021;21:111. doi:10.1186/s12874fD21fD1308fB
- 27 Combescure C, Foucher Y, Jackson D. Meta@analysis of single@arm survival studies: a distributionffree approach for estimating summary survival curves with random effects. *Stat Med* 2014;33:2521@7. doi:10.1002/sim.6111

- 28 Damuzzo V, Agnoletto L, Leonardi L, Chiumente M, Mengato D, Messori A. Analysis of Survival Curves: Statistical Methods Accounting for the Presence of LongITerm Survivors. *Front Oncol* 2019;9:453. doi:10.3389/fonc.2019.00453
- 29 Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated randomEffects metaEanalyses. *Res Synth Methods* 2019;10:83EP8. doi:10.1002/ jrsm.1316
- 30 Higgins JP, Thompson SG. Quantifying heterogeneity in a metal analysis. Stat Med 2002;21:1539[58. doi:10.1002/sim.1186
- 31 Egger M, Davey Smith G, Schneider M, Minder C. Bias in metall analysis detected by a simple, graphical test. *BM*/ 1997;315:629EB4 doi:10.1136/bmj.315.7109.629
- 32 Duval S, Tweedie R. Trim and fill: A simple funnel[plot[based method of testing and adjusting for publication bias in meta[] analysis. *Biometrics* 2000;56:455[63. doi:10.1111/j.0006] 341X.2000.00455.x
- 33 Guyatt GH, Oxman AD, Vist GE, et al, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924E. doi:10.1136/ bmj.39489.470347.AD
- 34 Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ* 2015;350:h870. doi:10.1136/bmj.h870
- 35 Andrews PJ, Pendolino AL, Ottaviano G, et al. Olfactory and taste dysfunction among mildIboImoderate symptomatic COVIDIL 9 positive health care workers: An international survey. *Lanyngoscope Investig Otolaryngol* 2020;5:1019[I28. doi:10.1002/Ii02.507
- 36 Cousyn L, Sellem B, Palich R, et al, COVIDOME 9 PSL group. Olfactory and gustatory dysfunctions in COVIDE 9 outpatients: A prospective cohort study. *Infect Dis Now* 2021;51:440[4. doi:10.1016/j. idnow.2021.03.004
- 37 DelliEra V, Farri F, Garzaro G, Gatto M, Aluffi Valletti P, Garzaro M. Smell and taste disorders during COVIDEL9 outbreak: CrossEsectional study on 355 patients. *Head Neck* 2020;42:1591E. doi:10.1002/ hed.26288
- 38 Fjaeldstad AW. Prolonged complaints of chemosensory loss after COVIDII 9. Dan Med J 2020;67:A05200340.
- 39 GarclaCAzorth D, AbildDa MJA, Aguirre MEE, et al, Spanish neuroCOVID registry group. Neurological presentations of COVIDII 9: Findings from the Spanish Society of Neurology neuroCOVIDII 9 registry. J Neurol Sci 2021;423:117283. doi:10.1016/j.jns.2020.117283
- 40 Horton DB, Barrett ES, Roy J, et al. Determinants and Dynamics of SARS/ECV/I2 Infection in a Diverse Population: 6IMonth Evaluation of a Prospective Cohort Study. J Infect Dis 2021;224:1345[56. doi:10.1093/infdis/jiab411
- 41 Kumar V, Singla S, Gupta N, et al. The incidence of anosmia in patients with laboratory/Econfirmed COVID 19 infection in India: An observational study. J Anaesthesiol Clin Pharmacol 2021;37:51E6. doi:10.4103/joacp.JOACP\_653\_20
- 42 Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVIDE 9 Patients. J Korean Med Sci 2020;35:e174. doi:10.3346/jkms.2020.35.e174
- 43 Miyazato Y, Morioka S, Tsuzuki S, et al. Prolonged and LateIDnset Symptoms of Coronavirus Disease 2019. Open Forum Infect Dis 2020;7:a507.
- 44 Prajapati DP, Shahrvini B, Said M, Srinivas S, DeConde AS, Yan CH. Assessment of patient recognition of coronavirus disease 2019 (COVIDE19)Eassociated olfactory loss and recovery: a longitudinal study. Int Forum Allergy Rhinol 2021;11:1529E7. doi:10.1002/ alr.22820
- 45 Printza A, Katotomichelakis M, Metallidis S, et al. The clinical course of smell and taste loss in COVIDD19 hospitalized patients. *Hippokratia* 2020;24:66I71.
- 46 Printza A, Katotomichelakis M, Valsamidis K, et al. Smell and Taste Loss Recovery Time in COVIDII 9 Patients and Disease Severity. J Clin Med 2021;10:966. doi:10.3390/jcm10050966
- 47 Rashid RA, Zgair A, AllAni RM. Effect of nasal corticosteroid in the treatment of anosmia due to COVIDII 9: A randomised doubleIblind placeboItcontrolled study. Am J Otolaryngol 2021;42:103033. doi:10.1016/j.amjoto.2021.103033
- 48 Riestra Dayora J, Yanes Diaz J, Esteban Danchez J, et al. Longflerm follow Dip of olfactory and gustatory dysfunction in COVID 19: 6 months case Dentrol study of health workers. *Eur Arch Otorhinolaryngol* 2021;278:4831 [Jr. doi:10.1007/s00405[D21]] 06764 [Jy
- 49 Bosciola Rizzo P, Hummel T, Hopkins C, et al. High prevalence of long@erm olfactory, gustatory, and chemesthesis dysfunction in postICOVIDI19 patients: a matched caseEcontrol study with one year followIpu suing a comprehensive psychophysical evaluation. *Rhinology* 2021;59:517E27. doi:10.4193/Rhin21.249
- 50 Erskine SE, Philpott CM. An unmet need: Patients with smell and taste disorders. *Clin Otolaryngol* 2020;45:1971203. doi:10.1111/ coa.13484

- 51 Costa KVTD, Carnalba ATL, Rocha KW, Andrade KCL, Ferreira SMS, Menezes PL. Olfactory and taste disorders in COVIDIL 9: a systematic review. *Braz J Otorhinolaryngol* 2020;86:781[92. doi:10.1016/j. bjorl.2020.05.008
- 52 Hopkins C, Surda P, Vaira LA, et al. Six month follow[µp of selffreported loss of smell during the COVID[1] 9 pandemic. *Rhinology* 2021;59:26[]31.
- 53 Cavazzana A, Larsson M, M⊡nch M, H⊡hner A, Hummel T. Postinfectious olfactory loss: A retrospective study on 791 patients. Laryngoscope 2018;128:10⊡. doi:10.1002/lary.26606
- 54 Butowt R, von Bartheld CS. Anosmia in COVIDD19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. *Neuroscientist* 2021;27:582E603. doi:10.1177/1073858420956905
- 55 Liang F, Wang Y. COVIDE 9 Anosmia: High Prevalence, Plural Neuropathogenic Mechanisms, and Scarce Neurotropism of SARS COVE?Viruses 2021;13:2225. doi:10.3390/v13112225
- 56 Tan CJIW, Tan BKJ, Tan XY, et al. Neuroradiological Basis of COVIDE 9 Olfactory Dysfunction: A Systematic Review and Meta[Analysis. Laryngoscope 2022;132:1260[74.
- 57 de Melo GD, Lazarini F, Levallois S, et al. COVIDEI 9/Ielated anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. *Sci Transl Med* 2021;13:eabf8396. doi:10.1126/scitranslmed.abf8396
- 58 Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019EnCoV on the epithelial cells of oral mucosa. *Int J Oral Sci* 2020;12:8. doi:10.1038/s41368ED20ED074Ex
- 59 LozadalNur F, ChainanilWu N, Fortuna G, Sroussi H. Dysgeusia in COVIDL 9: Possible Mechanisms and Implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:344Ib. doi:10.1016/j. 0000.2020.06.016
- 60 Imam SA, Lao WP, Reddy P, Nguyen SA, Schlosser RJ. Is SARSIE OVID (COVIDIE 9) postviral olfactory dysfunction (PVOD) different from other PVOD?World / Otorhinolaryngol Head Neck Surg 2020;6(Suppl 1):S26(B2. doi:10.1016/j.wjorl.2020.05.004
- 61 Sorokowski P, Karwowski M, Misiak M, et al. Sex Differences in Human Olfaction: A Meta[Analysis. *Front Psychol* 2019;10:242. doi:10.3389/fpsyg.2019.00242
- 62 Williams JA, Bartoshuk LM, Fillingim RB, Dotson CD. Exploring Ethnic Differences in Taste Perception. *Chem Senses* 2016;41:449L56. doi:10.1093/chemse/bjw021
- 63 Gebhard C, Regitz[Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVIDE 9 outcomes in Europe. *Biol Sex Differ* 2020;11:29. doi:10.1186/s13293[D20ED0304E]
- 64 Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID⊡ 9 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X⊡hromosome in Females Be Protective against SARS□ CoVID Compared to the Single X⊡chromosome in Males?*Int J Mol Sci* 2020;21:3474. doi:10.3390/ijms21103474
- 65 Lane AP, Turner J, May L, Reed R. A genetic model of chronic rhinosinusitisDassociated olfactory inflammation reveals reversible functional impairment and dramatic neuroepithelial reorganization. J Neurosci 2010;30:2324ID. doi:10.1523/JNEUROSCI.4507ID9.2010

- 66 Chen M, Reed RR, Lane AP. Acute inflammation regulates neuroregeneration through the NFIkB pathway in olfactory epithelium. *Proc Natl Acad Sci U S A* 2017;114:8089[D4. doi:10.1073/pnas.1620664114
- 67 Pedrotti M, Spaccasassi A, Biasioli F, Fogliano V. Ethnicity, gender and physiological parameters: Their effect on in vivo flavour release and perception during chewing gum consumption. *Food Res Int* 2019;116:57[JP.0. doi:10.1016/j.foodres.2018.12.019
- 68 Zeng M, Wang DY, Mullol J, Liu Z. Chemosensory Dysfunction in Patients with COVIDID 9: What Do We Learn from the Global Outbreak?Curr Allergy Asthma Rep 2021;21:6. doi:10.1007/ s11882ID20ID0987I5
- 69 Eliyan Y, Wroblewski KE, McClintock MK, Pinto JM. Olfactory Dysfunction Predicts the Development of Depression in Older US Adults. *Chem* Senses 2021;46:bjaa075. doi:10.1093/chemse/bjaa075
- 70 Rebholz H, Braun ŘJ, Ladage D, Knoll W, Kleber C, Hassel AW. Loss of Olfactory Function/Early Indicator for Covid[19, Other Viral Infections and Neurodegenerative Disorders. *Front Neurol* 2020;11:569333. doi:10.3389/fneur.2020.569333
- 71 Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months After COVIDE 9 Infection. JAMA Netw Open 2021;4:e210830. doi:10.1001/jamanetworkopen.2021.0830
- 72 Huang C, Huang L, Wang Y, et al. 6[month consequences of COVIDL9 in patients discharged from hospital: a cohort study. *Lancet* 2021;397:220[B2. doi:10.1016/S0140[L6736(20) 32656[B
- 73 Vihta KID, Pouwels KB, Peto TEA, et al. OmicronIassociated changes in SARSICoVID symptoms in the United Kingdom. medRxiv: the preprint server for health sciences. 2022:2022.01.18.22269082. doi:10.1101/2022.01.18.22269082.
- 74 Meng B, Abdullahi A, Ferreira IATM, et al, CITIIDINIHR BioResource COVIDII 9 Collaboration, Genotype to Phenotype Japan (G2PIJapan) Consortium, EcuadorICOVID19 Consortium. Altered TMPRS52 usage by SARSICoVID Omicron impacts infectivity and fusogenicity. *Nature* 2022;603:706II 4. doi:10.1038/541586ID22ID4474IX
- 75 Nishiura H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodríguez I Morales AJ. Relative Reproduction Number of SARSICoVI2 Omicron (B. 1.1.529) Compared with Delta Variant in South Africa. J Clin Med 2021;11:30. doi:10.3390/jcm11010030
  76 Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of
- 76 Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVIDE19 in patients presenting with influenzaElike symptoms. Int Forum Allergy Rhinol 2020;10:806E13. doi:10.1002/alr.22579
- 77 Hintschich CA, Niv MY, Hummel T. The taste of the pandemic contemporary review on the current state of research on gustation in coronavirus disease 2019 (COVIDE19). Int Forum Allergy Rhinol 2022;12:210E. doi:10.1002/alr.22902
- 78 Vaira LA, Hopkins C, Petrocelli M, et al. Do olfactory and gustatory psychophysical scores have prognostic value in COVIDII 9 patients? A prospective study of 106 patients. *J Otolaryngol Head Neck* Surg 2020;49:56. doi:10.1186/s40463ID20ID0449[y

#### Supplementary information: additional material